The increasing demand for early detection of diseases drives the efforts to develop more and more sensitive techniques to detect biomarkers in extremely low concentrations. Electromagnetic modes at the surface of one dimensional photonic crystals, usually called Bloch surface waves, were demonstrated to enhance the resolution and constitute an attractive alternative to surface plasmon polariton optical biosensors. We report on the development of Bloch surface wave biochips operating in both label-free and fluorescence modes and demonstrate their use in ovalbumin recognition assays.
INTRODUCTION
Recently, Bloch surface waves (BSW) propagating at the surface of truncated one dimensional photonic crystals 1,2 (1D-PC) have been suggested for label-free biosensors based on optical configurations similar to those used in surface plasmon resonance (SPR) 3, 4 , including angularly resolved detection modes. BSW biosensors feature very low angular resonance widths compared to that of SPR, due to the low losses in the dielectric stacks 5 . Furthermore, the optimization of the 1D-PC stack, in terms of geometry and materials, offers the possibility to improve the label-free operation, by tuning the resonance position and width 6, 7 .
When targeting analytes at low concentrations, label-free biosensing may suffer from less-than-ideal suppression or referencing of unspecific effects and yield a non-adequate limit of detection (LoD) . Coupling, in a single instrument, the label-free operation to a complementary detection system relying on the detection of fluorescent labels leads to a multimodal analysis and can decrease the LoD. The strong field localization and enhancement at the 1D-PC surface, and the absence of quenching, favor utilizing BSW coupled fluorescence emission 8, 9 . In such a coupled configuration, the BSW properties are exploited in two ways. First, the BSW angular resonance position is tracked as a label-free signal. Second, the BSW coupled emission yields a specific fluorescence detection whenever a labelling step is performed.
We report on the development and results of a combined label-free and fluorescence biosensing platform utilizing disposable biochips. As described in our previous works 10, 11 , a new optical system has been designed and fabricated, combining SPR-like angularly resolved resonance and the detection of fluorescent labels. All analysis can be performed in a parallel manner for multiple spots that are arranged as a one-dimensional array inside a microfluidic channel. In order to enable for later on disposable use, injection molded polymer substrates have been prepared and coated with low loss 1D-PC. Here we demonstrate the use of this multimode platform in ovalbumin recognition assays.
BSW BIOCHIPS
BSW are localized at the interface between a finite 1D-PC and an external medium by Bragg reflection and total internal reflection (TIR) on the two sides of the interface, respectively 4 . Like in SPR, the excitation of a BSW at a given
Si(D2 (a) The specific (a-OVA) and non-specific (a-Ang2) antibodies immobilization starts with the coupling of the silane with 1% (v/v) glutaraldehyde (GAH) (Sigma-Aldrich) solution in 100 mM sodium bicarbonate buffer (pH 8.5) in the presence of 0.1 mM NaCNBH 3 (sodium cyanoborohydride, Sigma-Aldrich) for 1 h at room temperature. A further sonication in DI water was performed prior to thoroughly rinsing the biochips with DI water. A 0.5 mg/ml (40 μl) solution of Protein G (PtG) (Thermo Scientific) in sodium bicarbonate buffer was dropped on the sensing area, allowed to react for 1 h at room temperature, and then removed by washing with D-PBS 1X. The role of PtG is to properly orient the capture antibodies and maximize their recognition efficiency.
After PtG immobilization we proceeded with the definition of the two sensitive regions. These are separated from each other by a permanent marker that is used to draw a line in the middle of the biochip channel, that works as a hydrophobic barrier for the antibodies solutions during immobilization. We incubated overnight at 4 °C a-Ova (8 µM, 20 µl) in one region of the biochip and a non-specific anti-Angiopoietin 2 (R&D Systems) antibody (a-Ang2) (20 µg/ml, 20 µl) in the other region, as a negative control. After a washing step with D-PBS 1X the chip was blocked with BSA (10 mg/ml) for 1 h at room temperature.
Immediately before use the surface of the biochips was treated with a regeneration solution made of 100 mM glycine (Sigma-Aldrich) and HCl with a pH of 2.0 at ambient temperature. This step improves the recovery of surface reactivity after the blocking step in BSA, because any adlayers should be removed. All reagents such as ethanol (99.8%), sulfuric acid (95%), 30% hydrogen peroxide solution and phosphate buffer saline (D-PBS 1X, pH 7.4) were obtained from Sigma-Aldrich and were used as it is.
Finally the biochip is rinsed with D-PBS 1X buffer again, is topped with the microfluidic element and is mounted mounted via a temperature controlled support in the optical system.
Label-Free assay
Once the biochip is mounted on the optical system the microfluidic channel is filled with D-PBS 1X and the position of the BSW resonance is tracked as a function of time in all positions along the illuminated strip. All injection and recirculation steps are performed at a flow rate of 5.5 μl/s. After acquiring the signal for a convenient time interval to be used as a baseline, we started injecting the OVA solutions in D-PBS 1X according to the following procedure: 1) Washing with 500 µl D-PBS 1X; 2) OVA sample injection (60 µl); 3) recirculation of the solution by backward/forward pumping (50 cycles of 30 µl); 4) Washing with 1000 µl D-PBS 1X; 5) Regeneration with 100mM Glycine-HCl pH 2.0. We repeated the procedure for the following OVA concentrations in D-PBS 1X: 0.7 nM, 2.1 nM, 6.3 nM, 18.9 nM, 56.7 nM, 170 nM and 467 nM. Such molar concentrations correspond to the following weight concentrations: 0.03 μg/ml, 0.09 μg/ml, 0.27 μg/ml, 0.81 μg/ml, 2.43 μg/ml, 7.29 μg/ml and 20 μg/ml. Figure 4 presents the kinetic curves obtained after injecting OVA at three concentrations (0.03 μg/ml, 0.27 μg/ml, 2.43 μg/ml). The angular position of the BSW resonance measured in CCD pixel (1 pixel = 0.856 mdeg) is plotted as a function of time. The kinetic signals measured in two different spots in the a-OVA region of the biochip are shown. In both cases the reference signals measured in two separate spots of the a-Ang2 negative control region on the biochip were subtracted. We observe that the signal response increases with the injected OVA concentrations. At the end of the OVA recirculation and after washing with D-PBS 1X the signal decreases to a stable residual value that is related to the amount of OVA captured at the surface. In Figure 5 , we show the residual BSW resonance shift (in CCD pixels) after OVA injection and washing with buffer, for two different OVA concentrations (7.29 μg/ml and 20 μg/ml). The surface of the biochip was probed by the illumination beam in 108 spots. The spots from 0 to 50 are in the a-OVA region, those from 51 to 64 are in the hydrophobic marker region, and those from 65 to 107 are in the a-Ang2 negative reference region. The residual shift is homogeneous in the two regions and the average value is larger in the signal region with respect to the negative reference. The signals measured during the assays in all spots, and similar to those shown in Figure 4 for just two spots, were averaged over several spots in the signal (PtG/a-OVA) and in the reference region (PtG/a-Ang2). The number of spots in the averaging varies between 14 and 40, being around 30 for the majority of the data sets. Then the average signals obtained for the signal and reference regions were subtracted to compensate for any drift. OVA concentration, C (nM) Figure 6 -Cumulated label-free signals extracted from measurements for all OVA concentrations, similar to those shown in Figure 4 . The green dots (light grey) correspond to the cumulated residual shift after washing with PBS. The blue dots (dark grey) were calculated summing the mean maximum shift for the given concentration to the residual shifts for the concentrations injected before.
In Figure 6 , the cumulated label-free signal at the end of the incubation of OVA concentrations (blue/dark grey dots) can be fitted to the model
) (blue/light grey curve), with values for the parameters reported in Table 1 The blue (dark grey) fitting curve in Figure 6 confirms that the binding process follows the expected behaviour for a Langmuir isotherm 19 . However the presence of a large non-zero d 0 distorts the curve in the limit of small concentrations, indicating the presence of a parasitic signal due to non-specific binding at the biochip surface. Probably such behaviour is due to an insufficient blocking of the biochip surface that adsorbs OVA biomolecules not-specifically in open binding sites. This result suggests that care should be taken to block the biochip surface with the aim to reduce d 0 as much as possible, ideally down to zero. From the analysis of the data reported in Figure 6 we can determine the limit of detection of the platform when operated in the label-free mode (LoD LF ) for the a-OVA/OVA system. Once d 0 is determined, we can assert that a signal can be detected if it differs from d 0 by more than twice the standard deviation (σ) of its associate measurement error. From the equality d max / (1 + (K A C) -1 ) = 2⋅σ, we then find LoD LF = 1.45 nM, corresponding to 60 ng/ml.
Fluorescence assay
From the analysis of the label-free experiments reported above it is clear that, for low OVA concentrations, the signals are affected by large errors due to not perfect compensation of parasitic effects (non-specific binding, local temperature and pressure effects, functionalization and immobilization inhomogeneities). The signals are immersed in a relatively large noise that does not permit to infer any information on OVA binding events. This limits the LoD LF as shown above. In this respect the complementary fluorescence assay permits to decrease of the limit of detection and discloses information on the OVA binding process.
As an example in Figure 7 (left) we show the result of a label-free assay carried out at an OVA concentration of 30 ng/ml. With respect to the measurements reported in the Section 4.2 here in the reference spot we immobilized antiHuman Serum Albumin (a-HSA) as a non-specific antibody (8 μM for 1 hour at ambient temperature). The curve is the difference between the averaged BSW minima positions in the signal and reference regions (22 and 42 spots of the a-OVA and a-HSA regions, respectively).
Starting from t=0 min, the assay was carried out according to the following protocol: 1) OVA injection (100 µl at 30 ng/ml); 2) Backward/forward recirculation (50 cycles of 25 µl); 3) Washing twice with 500 µl PBS; 4) Background Fluorescence measurement (integration time 1 ms); 5) Washing with 500 µl PBS; 6) Biotin-Labelled a-OVA* injection (100 µl at 10 µg/ml); 7) Backward/forward recirculation (50 cycles of 25 µl); 8) Washing twice with 500 µl PBS; 9) Labelled neutravidin (Dylight-650) injection (100 µl at 10 µg/ml); 10) Backward/forward recirculation (50 cycles of 25 µl); 11) Washing with 500 µl PBS; 12) Fluorescence Measurement (integration time 1 ms). All injections were carried out at a flow speed of 5.5 µl/s.
In Figure 7 (left) the time origin is set to the moment of injection of 100 μl of OVA solution. The various injections take place during the time intervals: (0, 9 min) OVA; (18, 27 min) biotinylated detection a-OVA*; (32, 41 min) Dylight650 labelled neutravidin. Fluorescence emission was measured in two time intervals: (12, 16 min) before labelling, (46, 50 min) after labelling with Dylight-650. As it can be seen the difference signal goes back to the starting level after injection of OVA at 30 ng/ml and subsequent washing with D-PBS 1X (t∼12 min). Such result confirms that the concentration 30 ng/ml is below the limit of detection of the label-free operation mode (for the used surface chemistry and protein immobilization procedures). After performing the second part of the assay, t∈(17, 46 min), the label-free signal is enhanced due to the mass loading effect when the detection antibody and the neutravidin bind to the OVA captured at the surface. One can observe a differential shift of the BSW resonances during the incubation of the species and a residual shift of about 1.5 pixel. However, the uncertainty of the measurement is still too large to claim label-free detection.
In Figure 7 (right) we show the result of the fluorescence measurement for the same OVA assay at 30 ng/ml. The curves represent the angular distributions of the background subtracted fluorescence emission in the reference (a-HSA) region (green) and in the signal (a-OVA) region (red). The curves were obtained by averaging 20 spots in either the reference or in the signal region. As it can be seen the fluorescence intensity in the signal region is well distinguished from the intensity in the reference region.
If we assume that for very low concentrations the density of bound OVA biomolecules, and therefore the fluorescence signal scales linearly, then we can estimate the limit of detection of the platform in the fluorescence mode:
/ Extracting data from Figure 7 (right) one gets LoD FLUO = 3.8±0.5ng/ml corresponding to 0.08± 0.01 nM. Such results demonstrate that the implementation of the fluorescence detection, not available in the SPR case, can lead to an improvement of the limit od detection, that is at least 10 times smaller than what found in the label-free mode.
CONCLUSIONS
The present work describes an approach based on BSW to combine label-free and fluorescent labels detection in a single biosensing platform. Low loss one dimensional photonic crystals featuring narrow surface wave resonances have been designed and fabricated on injection molded chips. A sandwich assay that detects ovalbumin has been successfully demonstrated. The tracking of the angular resonance position yields a label-free detection with LoD LF = 60 ng/ml. This result is supported by the clear difference of fluorescence intensities obtained on measurement and reference spots, indicating a much lower limit of detection LoD FLUO = 3.8 ng/ml. As a whole, successful combination of label-free and fluorescence modes in one optical detection system is achieved. Notably, the combination of angular and wavelength resolution in fluorescence mode yields new parameters for read-out that opens up new possibilities for designing different assays. The complete technological platform constituted by the instrument and the biochips is available for large scale production thus making the chip approach a valid candidate for disposable biosensor application.
